Abstract
Thirty-one patients with stage IIIA (N2) non-small-cell lung cancer were randomized to receive radiotherapy alone or chemotherapy with cisplatin and vinblastine followed by surgery. Response rates to induction chemotherapy and radiotherapy were 50% and 53.3% respectively. Complete surgical resection was possible for 62.5% of patients. Median survival times were 16.2 and 18.7 months for radiotherapy alone and chemotherapy-surgery respectively (P = Ns), with no long-term improvement in survival seen with combined-modality treatment.
Publication types
-
Clinical Trial
-
Comparative Study
-
Randomized Controlled Trial
MeSH terms
-
Adult
-
Aged
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
Carcinoma, Non-Small-Cell Lung / pathology
-
Carcinoma, Non-Small-Cell Lung / radiotherapy
-
Carcinoma, Non-Small-Cell Lung / therapy*
-
Chemotherapy, Adjuvant
-
Cisplatin / administration & dosage
-
Combined Modality Therapy
-
Female
-
Humans
-
Lung Neoplasms / pathology
-
Lung Neoplasms / radiotherapy
-
Lung Neoplasms / therapy*
-
Male
-
Middle Aged
-
Neoplasm Staging
-
Radiotherapy Dosage
-
Survival Analysis
-
Vinblastine / administration & dosage